Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity
Timna Varela Martins, … , Nicolas Riteau, José C. Alves-Filho
Timna Varela Martins, … , Nicolas Riteau, José C. Alves-Filho
Published October 1, 2024
Citation Information: JCI Insight. 2024;9(21):e171894. https://doi.org/10.1172/jci.insight.171894.
View: Text | PDF
Research Article Inflammation

The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity

  • Text
  • PDF
Abstract

Psoriasis is a chronic and recurrent inflammatory skin disease characterized by abnormal proliferation and differentiation of keratinocytes and activation of immune cells. However, the molecular driver that triggers this immune response in psoriatic skin remains unclear. The inflammation-related gene absent in melanoma 2 (AIM2) was identified as a susceptibility gene/locus associated with psoriasis. In this study, we investigated the role of AIM2 in the pathophysiology of psoriasis. We found elevated levels of mitochondrial DNA in patients with psoriasis, along with high expression of AIM2 in both the human psoriatic epidermis and a mouse model of psoriasis induced by topical imiquimod (IMQ) application. Genetic ablation of AIM2 reduced the development of IMQ-induced psoriasis by decreasing the production of type 3 cytokines (such as IL-17A and IL-23) and infiltration of immune cells into the inflammatory site. Furthermore, we demonstrate that IL-17A induced AIM2 expression in keratinocytes. Finally, the genetic absence of inflammasome components downstream AIM2, ASC, and caspase-1 alleviated IMQ-induced skin inflammation. Collectively, our data show that AIM2 is involved in developing psoriasis through its canonical activation.

Authors

Timna Varela Martins, Bruno Marcel Silva de Melo, Juliana Escher Toller-Kawahisa, Gabriel Victor Lucena da Silva, Conceição Elidianne Aníbal Silva, Isadora Marques Paiva, Gabriel Azevedo Públio, Marcos Henrique Rosa, Cacilda da Silva Souza, Dario Simões Zamboni, Fernando Q. Cunha, Thiago Mattar Cunha, Bernhard Ryffel, Nicolas Riteau, José C. Alves-Filho

×

Figure 1

AIM2 is required for the development of experimental psoriasis.

Options: View larger image (or click on image) Download as PowerPoint
AIM2 is required for the development of experimental psoriasis.
(A) Plas...
(A) Plasma concentration of mtDNA (mtDNA/nDNA copies/μL) in healthy individuals (n = 16) and patients with psoriasis (n = 13). (B) Heatmap showing the differentially expressed genes (DEGs) between lesioned and nonlesioned psoriatic skin from 5 databases, using a blue-to-red continuous color scale. (C) AIM2 expression in skin biopsy samples from healthy controls, nonlesioned, and lesioned sites from patients with psoriasis, as determined by transcriptome analysis in 4 published datasets. (D) Schematic illustration of psoriasis-like model induction using IMQ, applied for 6 days on the backs of the mice. (E) Daily measurement of back-skin thickness after topical IMQ application in WT mice. Untreated mice served as controls (n = 6 per group). (F) Time course of relative Aim2 mRNA expression in IMQ-treated and untreated WT mice, normalized to Gapdh in whole-skin lysates, evaluated by qPCR (n = 6 per group). (G) Back skin thickness (Δ) measured by caliper daily after IMQ application in WT and Aim2–/– mice. Untreated WT mice were used as controls (n = 6 per group). (H) Representative pictures of inflammation in shaved back skin. (I) H&E staining of back skin sections before IMQ. Naive WT mice were used as controls. Images were acquired at 20× magnification. Scale bar: 100 μm (n = 6 per group). (J) Relative mRNA expression of Kr14, Lcn2, and S100a9 genes in whole skin lysates evaluated by qPCR and normalized to Gapdh (n = 6 per group). Data are representative of 2–3 independent experiments and are shown as mean ± SEM. Statistical significance was evaluated by 2-tailed unpaired Student’s t test in A, 1-way ANOVA with Bonferroni post hoc test in C and J, and 2-way ANOVA followed by Bonferroni’s post hoc test in E–G. *P < 0.05, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts